BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer.

Despite the availability of several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), most patients with non-small-cell lung cancer (NSCLC) eventually develop resistance to these agents. Notably, In vitro activity of BLU-945 as a single agent and in combination with osimertinib was tested in engineered In vitro BLU-945 demonstrated inhibited cell viability and growth of Our findings demonstrate the preclinical and early clinical activity of BLU-945 in

Informations de copyright

© The Author(s), 2024.

Déclaration de conflit d'intérêts

S.M.L. reports grants from AstraZeneca, BeiGene, Bristol Myers Squibb, Boehringer-Ingelheim, Bridge BioTherapeutics, Daichii-Sankyo, Eli Lily, Gilead, GlaxoSmithkline, Jiangsu Hengrui Medicine, J Ints Bio, Oscotec, Roche, Takeda, and Yuhan. S.S.S. is a shareholder of Blueprint Medicines Corporation. C.C. is an employee of and a shareholder of Blueprint Medicines Corporation. Y.A.M. is an employee of and a shareholder of Blueprint Medicines Corporation. R.W. is a shareholder of Blueprint Medicines Corporation. Z.Z. is a shareholder of Blueprint Medicines Corporation. L.E.T.-M. reports work was conducted as an employee of Blueprint Medicines Corporation and is currently a shareholder of Blueprint Medicines Corporation. F.S. is a shareholder of Blueprint Medicines Corporation. F.A. is an employee of and a shareholder of Blueprint Medicines Corporation. T.A.D. is an employee of and a shareholder of Blueprint Medicines Corporation. J.H. is an employee of Blueprint Medicines Corporation and a shareholder of Blueprint Medicines Corporation. A.Z. is a shareholder of Blueprint Medicines Corporation. J.R. reports consulting fees or honoraria from Amgen, AstraZeneca, BioAtla, G1 Therapeutics, Genentech, Guardant Health, Jazz, Janssen, Sanofi-Genzyme, Summit, and Takeda Pharmaceuticals, and has also been contracted for research (institutional) with AstraZeneca, BioAtla, Blueprint Medicines, Enliven, EpimAb Biotherapeutics, LOXO Oncology, ORIC, and Redcloud. D.H.L. reports personal fees from AbbVie, AstraZeneca, BC World Pharm, Boehringer-Ingelheim, Bristol-Myers Squibb, ChongKeunDang, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Ono, Pfizer, Roche, ST Cube, Takeda Oncology, and Yuhan, and non-financial support from Blueprint Medicines Corporation and Takeda Oncology outside the submitted work. B.C.C. reports grants from AbbVie, AstraZeneca, Bayer, Blueprint Medicines Corporation, Champions Oncology, Dizal Pharma, Dong-A ST, Eli Lilly, GI Innovation, Janssen, MedPacto, Merck Sharp & Dohme, MOGAM Institute, Novartis, Ono, Yuhan, and consultancy fees from AstraZeneca, Blueprint Medicines Corporation, Bristol Myers Squibb, Boehringer-Ingelheim, Eli Lilly, Janssen, MedPacto, Merck Sharp & Dohme, Novartis, Ono, Pfizer, Roche, Takeda, and Yuhan and currently owns stock in BridgeBio Therapeutics, Gencurix Inc, KANAPH Therapeutic Inc, TheraCanVac Inc., has served on a scientific advisory board for KANAPH Therapeutic Inc, receives royalties for Champions Oncology and is the founder of Daan Biotherapeutics.